# Syrrx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/syrrx

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.syrrx.com
- Total disclosed funding: $74M
- Latest round: Series C (Jan 1, 2001)
- Investors on record: 8

## About

Syrrx is a pharmaceutical company specializing in innovative solutions for high-throughput structure determination and screening. They provide advanced research tools to facilitate intricate studies in cellular functions and immune responses.Founded in San Diego, US, Syrrx focuses on delivering pharmaceutical solutions. The company was acquired by Takeda Pharmaceutical Company Limited in February 2005 for USD 270 mn. The founder’s background and previous ventures are not detailed in available sources.Syrrx specializes in delivering advanced pharmaceutical solutions, primarily focusing on high-throughput structure determination and high-throughput screening (HTS). Their offerings encompass a wide range of research tools aimed at elucidating molecular mechanisms, cellular functions, and immune responses. Core products include comprehensive research kits for DNA, RNA, and histone preparation, along with specialized assays like DNA bisulfite conversion and methylation quantification. Their clientele comprises leading research institutions and pharmaceutical companies engaged in genetics, cell biology, and disease pathology. Syrrx's products are marketed primarily in North America and Europe, addressing the needs of professionals in academic research, biotech, and pharmaceutical sectors.Syrrx generates revenue through a B2B model, providing tailored pharmaceutical products and services to research institutions and pharmaceutical companies. Transactions typically involve direct sales of research kits, assays, and customized solutions, with structured pricing based on the specific products or packages selected by clients. These transactions may include long-term partnerships for ongoing research support, where clients subscribe to specific services or products based on their project requirements. While detailed pricing information for individual products is not disclosed, the company offers diverse solutions such as antibody panels, epigenetic modification assays, and sample preparation kits, all designed to facilitate advanced research in various scientific fields.Following its acquisition in February 2005, Syrrx's growth strategy may involve leveraging Takeda's resources to develop new products and enhance their market presence. Although specific upcoming products or expansion plans into new geographic regions were not detailed, the acquisition provides potential for increased investment in research and development initiatives.

## Funding rounds

- Series C, Jan 1, 2001, $54M — Versant Ventures, Presidio Partners, Bay City Capital, Lombard Odier Asset Management, MPM BioImpact, CIBC, Jaspersoft Corporation, Wanger Asset Management
- Series B, Oct 3, 2000, $20M — Versant Ventures, Presidio Partners, Bay City Capital, Lombard Odier Asset Management, MPM BioImpact

## Investors

- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series B, Series C
- Presidio Partners (https://capitalatlas.ai/funds/presidio-partners) — Series B, Series C
- Bay City Capital (https://capitalatlas.ai/funds/bay-city-capital) — Series B, Series C
- Lombard Odier Asset Management — Series B, Series C
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series B, Series C
- CIBC — Series C
- Jaspersoft Corporation — Series C
- Wanger Asset Management — Series C